Fresenius Kabi USA, LLC

Form 483 issued October 13, 2023 · Grand Island, New York

Inspection
Oct 4 – Oct 13, 2023
Observations
2
Pages
5
FEI number
3001833549

In short: On October 13, 2023, FDA issued a Form 483 with 2 observations to Fresenius Kabi USA, LLC in Grand Island, New York (FEI 3001833549) after an inspection that ran Oct 4 – Oct 13, 2023. The investigators were Jazmine N. Brown and Mindy M. Chou. Most observations concern production and quality system; the most-cited regulation is 21 CFR 211.113 (control of microbiological contamination).

At a glance

Production and quality system account for 2 of 2 observations.

Production1
Quality system1

Most cited: 21 CFR 211.113(b) (1×) · 211.192 (1×)

What FDA observed

Preview: the opening words of each observation
  1. 01

    Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are…

  2. 02

    There is a failure to thoroughly review any unexplained discrepancy whether or not the batch…

The full 483

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at Fresenius Kabi USA, LLC?

FDA listed 2 observations on this Form 483, mostly about production and quality system. The most-cited regulation is 21 CFR 211.113 (control of microbiological contamination). The opening words of each observation are shown on this page.

Who inspected Fresenius Kabi USA, LLC?

Jazmine N. Brown and Mindy M. Chou are named on this Form 483, for the inspection of Oct 4 – Oct 13, 2023. Each investigator has a profile showing what they cite most.

When was Fresenius Kabi USA, LLC inspected by FDA?

The inspection ran Oct 4 – Oct 13, 2023, and the Form 483 is dated October 13, 2023.

How do I get the full Form 483 for Fresenius Kabi USA, LLC?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free